Abstract: OBJECTIVE To investigate the clinical effect of apatinib in the neoadjuvant chemotherapy of massive cervical cancer(tumor diameter > 4 cm). METHODS Thirty-one cases patients of cervical cancer who were diagnosed in Jinhua Municipal Central Hospital with the diameter of the tumor > 4 cm were collected between June 2016 to January 2018. They were randomly divided into the treatment group(16 cases, cisplatin+paclitaxel+apatinib) and the control group(15 cases, cisplatin+ paclitaxel) for two cycles of chemotherapy. Chemotherapy-related complications, the changes of the tumor, operation time, operative blood loss and the postoperative complications were described to demosterate the role of apatinib played in neoadjuvant chemotherapy. RESULTS There was no significant difference in the diameter of tumors between the treatment group(4.74±0.51)cm and the control group(4.90±0.56)cm before chemotherapy. After chemotherapy, the diameter of tumors in the treatment group was (2.54±0.90)cm and that in the control group was (3.28±0.38)cm, the difference between the two groups had statistically significant(P<0.05). The operation time of the treatment group were (244.19±22.37)min and bleeding volume of the treatment group were (288.06±34.05)mL, while the operation time of the control group were (282.27±10.87)min and bleeding volume of the control group were (342.33±51.58)mL, there had significant differences in operation time and bleeding volume between the two groups(P<0.05). CONCLUSION Neoadjuvant chemotherapy combined with apatinib in patients with massive cervical cancer can reduce the size of the tumors with a better effect and it is conducive to the smooth operation.